

## SUPPLEMENTARY TABLE

**Supplementary Table S1: Baseline clinical and pathological characteristics of patients and primary tumors for the entire study cohort and the subsets of patients included on the two different tissue microarrays (TMAs)**

	Tissue Microarrays (TMAs)		
	All Patients (N = 304)	Primary Tumors (N = 217)	Synchronous LNM (N = 111)
	N (%)	N (%)	N (%)
<b>Age at diagnosis</b>			
Median (range)	50 (27–71)	51 (27–71)	51 (27–71)
< 50 years	154 (51%)	97 (45%)	52 (42%)
≥ 50 years	149 (49%)	118 (55%)	72 (58%)
Missing/unknown	1	2	0
<b>Histological grade</b>			
1/2	121 (49%)	80 (43%)	39 (43%)
3	125 (51%)	105 (57%)	52 (57%)
Missing/unknown	58	32	20
<b>Tumor size</b>			
≤ 20 mm	119 (40%)	84 (40%)	31 (28%)
> 20 mm	180 (60%)	128 (60%)	79 (72%)
Missing/unknown	5	5	1
<b>Nodal status</b>			
N0	92 (31%)	68 (33%)	0 (0%)
N+	203 (69%)	141 (67%)	111 (100%)
Missing/unknown	9	8	0
<b>Adjuvant chemotherapy</b>			
Yes	150 (49%)	101 (47%)	72 (65%)
No	152 (50%)	114 (53%)	39 (35%)
Missing/unknown	2	2	0
<b>Adjuvant endocrine therapy</b>			
Yes	156 (52%)	117 (54%)	70 (63%)
No	147 (48%)	99 (46%)	41 (37%)
Missing/unknown	1	1	0
<b>Adjuvant radiotherapy</b>			
Yes	214 (71%)	154 (72%)	84 (76%)
No	87 (29%)	60 (28%)	26 (24%)
Missing/unknown	3	3	1

(Continued)

<b>Tissue Microarrays (TMAs)</b>			
	<b>All Patients (N = 304)</b>	<b>Primary Tumors (N = 217)</b>	<b>Synchronous LNMs (N = 111)</b>
	<i>N (%)</i>	<i>N (%)</i>	<i>N (%)</i>
<b>Metastasis-free interval</b>			
Locally-advanced	47 (16%)	14 (7%)	15 (13%)
< 5 years	147 (48%)	124 (57%)	66 (60%)
≥ 5 years	110 (36%)	79 (36%)	30 (27%)
Missing/unknown	0	0	0
<b>Site of recurrence</b>			
Loco-regional	50 (17%)	38 (18%)	19 (17%)
Bone	56 (18%)	38 (18%)	21 (19%)
Lung	63 (21%)	45 (21%)	21 (19%)
Liver	133 (44%)	94 (43%)	50 (45%)
Missing/unknown	2	1	